ORGO Q1 2025 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$87M-21.2% YoY

Gross Profit

$63M72.6% margin

Operating Income

-$27M-30.9% margin

Net Income

-$19M-21.7% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-31.6%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$24M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$467M

Total Liabilities

$99M

Stockholders' Equity

$368M

Cash & Equivalents

$110M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$87M	$110M	-21.2%
Gross Profit	$63M	$81M	-22.5%
Operating Income	-$27M	-$4M	-594.3%
Net Income	-$19M	-$2M	-797.3%

Revenue Segments

Advanced Wound care

$80M92%

Surgical and Sports Medicine

$7M8%